![Journal for ImmunoTherapy of Cancer (@jitcancer) 's Twitter Profile](https://pbs.twimg.com/profile_images/1207683991958110210/JrtMlwSD_200x200.png)
Journal for ImmunoTherapy of Cancer
@jitcancer
The official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. #JITC Editor-in-Chief: Michael T. Lotze, MD
ID: 1150769339466952705
https://jitc.bmj.com/ 15-07-2019 14:09:25
5,5K Tweet
8,8K Followers
1,1K Following
![Journal for ImmunoTherapy of Cancer (@jitcancer) 's Twitter Profile Photo Journal for ImmunoTherapy of Cancer (@jitcancer) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1207683991958110210/JrtMlwSD_200x200.png)
Let’s take a closer look at recent #JITC article: “rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors” by Mitchell Ho, PhD & Dan Li from NCI Center for Cancer Research & NeoImmuneTech. 1/8
![Journal for ImmunoTherapy of Cancer (@jitcancer) on Twitter photo Let’s take a closer look at recent #JITC article: “rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors” by <a href="/MitchellHo/">Mitchell Ho, PhD</a> & <a href="/danli_502/">Dan Li</a> from <a href="/NCIResearchCtr/">NCI Center for Cancer Research</a> & <a href="/NeoImmuneTech/">NeoImmuneTech</a>. 1/8 Let’s take a closer look at recent #JITC article: “rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors” by <a href="/MitchellHo/">Mitchell Ho, PhD</a> & <a href="/danli_502/">Dan Li</a> from <a href="/NCIResearchCtr/">NCI Center for Cancer Research</a> & <a href="/NeoImmuneTech/">NeoImmuneTech</a>. 1/8](https://pbs.twimg.com/media/GWFz_UJXEAAHFz_.jpg)